Psoriasis Longitudinal Assessment and Registry (NCT00508547)
A Multicenter, Open Registry of Patients With Plaque Psoriasis Who Are Candidates for Systemic Therapy Including Biologics
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to further evaluate the safety of infliximab, ustekinumab, and guselkumab in patients with plaque and other forms of psoriasis. The study also includes patients receiving other therapies, such as non-biologic and other biologic agents. The registry also evaluates patient and disease characteristics, including patient-reported assessment of psoriatic arthritis (PsA); and clinical and quality of life outcomes.
Who can join: Review the eligibility criteria below.
Location: Clinical Research Facility — Birmingham, Alabama
Age range: 18 Years to 99 Years
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (320 Sites)
Showing the first 25 of 320 sites.
- Clinical Research Facility — Birmingham, Alabama
- Clinical Research Facility — Florence, Alabama
- Clinical Research Facility — Huntsville, Alabama
- Clinical Research Facility — Phoenix, Arizona
- Clinical Research Facility — Scottsdale, Arizona
- Clinical Research Facility — Tucson, Arizona
- Clinical Research Facility — Rogers, Arkansas
- Clinical Research Facility — Bakersfield, California
- Clinical Research Facility — Clovis, California
- Clinical Research Facility — Fountain Valley, California
- Clinical Research Facility — Fresno, California
- Clinical Research Facility — Loma Linda, California
- Clinical Research Facility — Los Angeles, California
- Clinical Research Facility — Mountain View, California
- Clinical Research Facility — Oxnard, California
- Clinical Research Facility — Redding, California
- Clinical Research Facility — Rolling Hills Estates, California
- Clinical Research Facility — San Diego, California
- Clinical Research Facility — San Ramon, California
- Clinical Research Facility — Santa Monica, California
- Clinical Research Facility — Sherman Oaks, California
- Clinical Research Facility — Upland, California
- Clinical Research Facility — Vallejo, California
- Clinical Research Facility — Colorado Springs, Colorado
- Clinical Research Facility — Englewood, Colorado
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Psoriasis
- Deucravacitinib Adherence Study — Winston-Salem, North Carolina
- An Open-label, Single-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Brodalumab in Pediatric Subjects — San Diego, California
- Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 — Birmingham, Alabama
- Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis — Birmingham, Alabama
- Prevention of Cardiovascular Disease and Mortality in Patients With Psoriasis or Psoriatic Arthritis — Scottsdale, Arizona
Explore by condition: All Psoriasis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.